SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Rhea-AI Summary
SAB Biotherapeutics (Nasdaq: SABS) closed an underwritten public offering on March 19, 2026 of 19,324,677 shares of common stock and pre-funded warrants for up to 2,753,246 shares at a public offering price of $3.85 per share (pre-funded warrants at $3.8499).
Gross proceeds were approximately $85 million before fees. The company granted underwriters a 30-day option to buy up to 3,311,688 additional shares. Net proceeds will primarily fund continued development and trials of SAB-142, manufacturing, regulatory activities, and general corporate purposes.
Positive
- Gross proceeds of approximately $85 million
- Net proceeds dedicated to SAB-142 clinical development
- Underwritten offering led by major banks (Jefferies, UBS, Citi, Barclays)
Negative
- Potential dilution from 19,324,677 shares and 2,753,246 pre-funded warrants
- Additional dilution risk from 30-day option for 3,311,688 shares
News Market Reaction – SABS
In the Mar 20 session, SABS declined 0.79%, reflecting a mild negative market reaction. Argus tracked a peak move of +2.6% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Offering priced | Negative | -9.1% | Pricing of $85M underwritten offering with shares and pre-funded warrants. |
| Mar 17 | Offering proposed | Negative | -9.1% | Launch of proposed underwritten offering to fund SAB-142 development. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Offering-related news for SABS has repeatedly coincided with single-day moves around -9.09%, indicating a consistent negative reaction pattern to dilution events.
Over recent weeks, SAB BIO has combined clinical and corporate milestones with multiple financing steps. Positive full-year 2025 results and additional Phase 1 SAB-142 data led to gains of 6.77%, while conference participation had little impact. In contrast, the March 2026 proposed and priced $85 million public offering announcements each saw -9.09% reactions. Today’s closing of that same offering follows this sequence, extending the capital-raising phase aimed at advancing SAB-142.
Key Terms
underwritten public offering financial
pre-funded warrants financial
exercise price financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the closing of an underwritten public offering of 19,324,677 shares of its common stock at a public offering price of
The Company intends to use the net proceeds received from this offering, together with its existing cash, cash equivalents and marketable securities, primarily to fund the continued development of our clinical stage product candidate, SAB-142 through ongoing and planned clinical trials, as well as for related manufacturing, regulatory, and operational activities, and for working capital and general corporate purposes.
Jefferies, UBS Investment Bank, Citigroup, and Barclays acted as joint book-running managers for the offering. Chardan acted as lead manager.
The securities described above were offered pursuant to a shelf registration statement on Form S-3 (No. 333-292482) that was filed with the U.S. Securities and Exchange Commission (the SEC) on December 29, 2025, and declared effective on January 7, 2026. This offering was made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A final prospectus supplement related to and describing the terms of the offering was filed with the SEC and is available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement and an accompanying prospectus related to the offering may also be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@jefferies.com; UBS Securities LLC, Attention: Prospectus Department, UBS Investment Bank, 11 Madison Avenue, New York, New York 10010 or by email at ol-prospectus-request@ubs.com; Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146; or Barclays Capital Inc. by calling (888) 603-5847, or by mail at Barclays c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.
About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit www.sab.bio.
Forward-Looking Statements
Certain statements made in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the development and clinical trial results of the Company’s T1D program and other discovery programs, and the use of proceeds from the public offering.
These statements are based on the current expectations of SAB BIO and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
CONTACTS
Investors:
Sheila Carlson
ir@sab.bio
Media:
Sheila Carlson
media@sab.bio
